https://www.thebodypro.com/tag/hepatitis-c

Hepatitis C

The Latest

magnifying glass

This Week in HIV Research: The Importance of Challenging Our Assumptions

Feb. 25, 2021: High HCV SVR among people using substances; geographic HIV care disparities among Black Americans; self-administered imiquimod vs. ASIL excision; PrEP uptake in syringe service programs.

By Barbara Jungwirth and Myles Helfand
rapid HIV test

This Week in HIV Research: Early Screening Matters, and Not Just for HIV

Feb. 11, 2021: Early comorbidity development among women living with HIV; type 2 heart attack frequency; assessing European-based CVD assessment tools; long-term cognitive dysfunction and HIV/hepatitis coinfection.

By Barbara Jungwirth and Myles Helfand
doctor patient hands

This Week in HIV Research: Health in Unity

Jan. 21, 2021: Dyad-level interventions in serodiscordant relationships; using social media to improve PrEP uptake; HCV prevalence among MSM; the irrelevance of doxycycline prophylaxis against mycoplasma genitalium.

By Barbara Jungwirth and Myles Helfand
prescription telemedicine

Can a Low-Contact, Minimal Monitoring Approach Become the New Normal for Treating Hepatitis C?

No baseline genotyping. Fewer in-person medical visits and lab tests. No need for refills. Could the future of HCV treatment take place almost entirely remotely?

By Terri Wilder, M.S.W.
Biden Harris

Will the Biden-Harris Administration Breathe Life Back Into Vital HIV and Hepatitis Programs?

We spoke with Amy Killelea at NASTAD, a major national health policy advocacy organization, about the priorities she sees in January 2021 and beyond.

By Terri Wilder, M.S.W.
COVID-19 mask profile

This Week in HIV Research: The Real-World Effects of COVID-19

Oct. 22, 2020: Impact of COVID-19 shutdowns on HIV viral suppression; unsuppressed HIV viral load despite no treatment failure; point-of-care rapid testing vs. lab testing; it's not about "what," it's about "when."

By Barbara Jungwirth and Myles Helfand
prison

Hepatitis C Treatment Barriers Persist Through the Cure Era, Especially in U.S.

For the most vulnerable populations disproportionately impacted by HCV in the U.S.—i.e., incarcerated people and people who inject drugs—treatment remains dangerously elusive, experts say.

By Ginger Skinner
Hep C virus

This Week in HIV Research: Hep C, That Other Epidemic Within an Epidemic

Sept. 3, 2020: A hepatitis C microelimination program for people living with HIV; PrEP concentrations and gender-affirming hormones; a collaborative intervention to improve opioid prescribing practices; TDF and fracture risk.

By Barbara Jungwirth and Myles Helfand
Annette Gaudino and Bryn Gay

With Several Curative Therapies for Hepatitis C on the Market, the Research Pipeline for Prevention Continues

The authors of an influential annual report on hepatitis C research and development talk through what's new and evolving in clinical science.

By Terri Wilder, M.S.W.
mouth to ear

This Week in HIV Research: Why Aren’t We Listening to Ourselves?

Aug. 13, 2020: HCV testing rates among people newly diagnosed with HIV; HCV treatment referrals ammong coinfected people; HIV mortality rates despite free treatment access; mysterious, plummeting CD4 test results.

By Barbara Jungwirth and Myles Helfand